Ropes & Gray advised Acumen Pharmaceuticals on the transaction. Acumen Pharmaceuticals (Nasdaq:ABOS) (“Acumen”) announced a global non-exclusive collaboration and license agreement with Halozyme Therapeutics (Nasdaq:HALO) (“Halozyme”). Acumen will...
Acumen Pharmaceuticals’ Global Collaboration and License Agreement with Halozyme Therapeutics
Goldfinch Bio’s Exclusive Global License Agreement with Karuna Therapeutics
Ropes & Gray represented Goldfinch Bio on the deal. Goldfinch Bio announced an exclusive global license agreement with Karuna Therapeutics under which Karuna will have development, manufacturing...
HUTCHMED’s License Agreement with Takeda Pharmaceutical
Ropes & Gray represented HUTCHMED on the deal. HUTCHMED (China) Limited and its subsidiary, HUTCHMED Limited announced an exclusive worldwide license agreement with Japan’s largest drugmaker Takeda...